

List of Contributors	
Introduction	p. 1
Cytotoxic Myocardial Disease: Preclinical Study	p. 7
The Role of Free Radical Formation in the Cardiotoxicity of Anthracycline	p. 9
The Role of Antioxidant Defenses in the Cardiotoxicity of Anthracycline	p. 47
In Vitro Models of the Cardiotoxicity of Anticancer Agents	p. 59
Pathologic Anatomy of Animal Models of the Cardiotoxicity of Anthracycline	p. 89
Methods of Reducing the Cardiotoxicity of Anthracycline	p. 114
Cytotoxic Myocardial Disease: Clinical Study	p. 171
The Diagnosis and Treatment of Drug-Induced Myocardial Disease	p. 173
The Role of Myocardial Biopsy in the Diagnosis of Anthracycline Toxicity	p. 198
Anthracycline Analogues and Carriers	p. 217
The Natural History of Anthracycline Cardiotoxicity in Children	p. 246
Agents for Clinical Protection against the Cardiotoxicity of Anthracycline	p. 256
The Schedule Dependency of the Cardiotoxicity of Adriamycin: Its Relevance to Pharmacokinetic Parameters	p. 278
Myocardial Disease: Radiation and Biologics	p. 287
Radiation-Induced Myocardial Disease	p. 289
The Cardiovascular Effects of Human Recombinant Cytokines	p. 296
Pericardial Disease	p. 329
Radiation-Induced Pericardial Disease	p. 331
The Pericardial Effects of Anticancer Drugs	p. 344
Other Cardiovascular Disease	p. 357
Drug-Induced Ischemic Syndromes	p. 359
Cardiac Arrhythmias Caused by Anticancer Drugs	p. 372
Index	p. 385

Table of Contents provided by Blackwell's Book Services and R.R. Bowker. Used with permission.